(This morbidity is similar to what is seen in greater than 50% of patients with melanoma who experience at least grade 3 toxicity with PD-1 and CTLA-4 antibody combination clinically and often require dose reductions or permanent discontinuations [34]). The gene discussed is PDCD1; the disease is melanoma.